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Abstract
Cell survival in complex, vascularized tissues, has been implicated as a major bottleneck in advancement of therapies based
on cardiac tissue engineering. This limitation motivates the search for small, inexpensive molecules that would
simultaneously be cardio-protective and vasculogenic. Here, we present peptide sequence QHREDGS, based upon the
fibrinogen-like domain of angiopoietin-1, as a prime candidate molecule. We demonstrated previously that QHREDGS
improved cardiomyocyte metabolism and mitigated serum starved apoptosis. In this paper we further demonstrate the
potency of QHREDGS in its ability to enhance endothelial cell survival, metabolism and tube formation. When endothelial
cells were exposed to the soluble form of QHREDGS, improvements in endothelial cell barrier functionality, nitric oxide
production and cell metabolism (ATP levels) in serum starved conditions were found. The functionality of the peptide was
then examined when conjugated to collagen-chitosan hydrogel, a potential carrier for in vivo application. The presence of
the peptide in the hydrogel mitigated paclitaxel induced apoptosis of endothelial cells in a dose dependent manner.
Furthermore, the peptide modified hydrogels stimulated tube-like structure formation of encapsulated endothelial cells.
When integrin avb3 or a5b1were antibody blocked during cell encapsulation in peptide modified hydrogels, tube formation
was abolished. Therefore, the dual protective nature of the novel peptide QHREDGS may position this peptide as an
appealing augmentation for collagen-chitosan hydrogels that could be used for biomaterial delivered cell therapies in the
settings of myocardial infarction.
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Introduction
In order to stimulate repair of damaged organs, many research
groups have looked towards various cell therapies. However, in the
vast majority of cases, injecting cells into a damaged organ/tissue
results in a large amount of the cells not remaining at the injury
site, while the cells that do remain undergo apoptosis due to lack of
nutrients and oxygen [1]. Consequently, novel methods are
required to keep cells localized to the injury site and ensure their
survival until a vascular network is created [2].
Hydrogels are used as the base biomaterial in many cell therapy
strategies as they provide a non-invasive option for cell injection
[3]. Since hydrogels can be mixed with cells in liquid state and
allowed to gel upon injection, these hydrogel cell suspensions can
be administered through a minimally invasive catheter injection
procedure. However, the problem of creating a stable vasculature
to ensure nutrient and oxygen supply to the injected cells still
remains.
To address this, efforts have focused on implanting endothelial
cells (EC) within or around biomaterials to help induce vascular
formation as well as the use of angiogenic growth factors to help
promote vessel formation [4,5,6,7]. The main caveat with using
growth factors in a clinical or commercial setting is their high cost
and susceptibility to denaturation [8]. Furthermore, it is difficult to
quality-control biomaterials modified with growth factors due to
the variable shelf-life of growth factors. Covalent or physical
immobilization may result in protein inactivation and blocking of
the active site. To solve this problem, it is possible to use short
peptide sequences that are derived from a specific growth factor to
stimulate a similar response in cells. These peptide sequences
would be more stable than their growth factor counterparts while,
also being less susceptible to conformational changes during
binding or encapsulation in biomaterials as they are short linear
chains of amino acids. Most importantly, synthetic peptides are
significantly more cost effective to produce than recombinant
human proteins.
One such peptide sequence of interest for use in biomaterials is
the novel angiopoietin-1 (ang1) based peptide QHREDGS [9].
This peptide sequence is based on the fibrinogen-like domain of
ang1. Previously, we reported that this peptide sequence was able
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to promote the survival of neonatal rat cardiomyocytes during
paclitaxel (taxol) treatment on glass slides treated with the
QHREDGS peptide conjugated to photocrosslinkable chitosan
[10]. Our laboratory further characterized this peptide’s function
in a collagen-chitosan hydrogel with encapsulated cardiomyocytes
finding that the peptide enhanced neonatal rat cardiomyocyte
morphology, viability and metabolic activity in a dose dependent
manner [11]. The cardio-protective effects of the peptide in
concert with the ease with which it can be incorporated into a
hydrogel for minimally invasive delivery make this platform
appealing as a potential therapy for post myocardial infarction
rehabilitation.
Upon myocardial infarction, the ventricular wall loses function-
al vasculature as well as cardiomyocytes. With time, a non-
contractile scar tissue composed of dense extracellular matrix and
fibroblasts will be formed. As a result, even if cells were implanted
with the aid of a biomaterial for cell localization, the lack of
vasculature would result in cell death due to the lack of oxygen and
nutrients motivating the need for the development of new
biomolecules that will be cardioprotective and enhance blood
vessel formation simultaneously. We hypothesised that the
QHREDGS peptide would exhibit beneficial effects on endothelial
cell survival and tube formation.
Here, we evaluated the effect of soluble QHREDGS peptide on
metabolism, permeability and nitric oxide (NO) release of
endothelial cell monolayers. Next, the peptide was covalently
immobilized to chitosan to create a collagen-chitosan hydrogel,
previously shown suitable for myocardial cell injection [11].
Monolayer studies of endothelial cells cultured on the surface of
the peptide modified collagen-chitosan hydrogel were performed.
These studies allowed us to determine the combined effect of the
hydrogel and peptide on endothelial cell phenotype, such as CD31
expression, vascular endothelial cadherin (VE-CAD) expression,
cell size and survival. Finally, studies of endothelial cells
encapsulated within the peptide modified hydrogel were per-
formed to determine which integrins mediate EC-peptide inter-
actions and to model implantation studies in vitro. Collectively our
findings suggest that QHREDGS stimulates endothelial cell-cell
interactions, enhances cell metabolism and promotes survival.
Materials and Methods
Endothelial Cell Maintenance
Dermal human microvascular endothelial cells (HMVEC-D)
were obtained (Lonza) and cultured as recommended in the
manufacturer’s instructions in full endothelial growth media. Cells
were cultured on plates coated with 50 mg/ml collagen I (10 min)
(Advanced Biomatrix). Microvascular endothelial cells (MS1 EC)
were obtained (ATCC) and cultured as previously described [9].
The human umbilical vein endothelial cells (HUVECs) were
received from Lonza (product number C2519A). The cells were
then expanded in endothelial cell growth medium-2 (EGM2),
which was obtained from Lonza, and frozen down at passage 3.
The final concentration of fetal bovine serum in the media was
2%. There was no bovine brain extract and a number of additives
were included in the culture media before use as per manufac-
turer’s instructions. They included: human epidermal growth
factor (hEGF), hydrocortisone, GA-1000, vascular endothelial
growth factor (VEGF), human basic fibroblast growth factor
(hFGF-B), insulin-like growth factor-1 (R3-IGF-1), ascorbic acid,
and heparin. The media was stored at 220uC and heated to 37uC
before use.
Peptide Modified Chitosan (UP-G113-QHREDGS)
QHREDGS peptide was conjugated to chitosan using 1-ethyl-
3-(3-dimethylaminopropyl) carbodiimide HCl (EDC) chemistry in
a similar fashion as previously described [10,11]. To determine the
dose response of the peptide, two different concentrations were
implemented, a 100 mM and 650 mM concentration of the peptide
in proportion to the amount of chitosan present. Chitosan (UP-
G113, Novamatrix) was dissolved at 20 mg/ml in 0.9% normal
saline and peptide at 10 mg/ml in PBS (Lonza). This solution was
then mixed with EDC and N-hydroxysulfosuccinimede (S-NHS)
dissolved in PBS to a final solution concentration of 5 mg/ml
chitosan and the two peptide concentrations: 100 mM for the low
peptide (0.5 mg/ml) concentration and 650 mM for the high
peptide (3.0 mg/ml) concentration. It should be noted that the
ratio of [EDC]/[peptide] and [S-NHS]/[EDC] was kept constant
in the two reaction mixtures at 0.8 and 2.75.
Chitosan-collagen Hydrogel Formulation
The chitosan-collagen hydrogel was created in a similar fashion
as previously described [11]. Briefly, the hydrogel had a final
concentration of 2.5 mg/ml each of chitosan and collagen;
consisted of 203.1 ml pure or peptide-modified chitosan mixed
with 100 ml 10X PBS, 681.2 ml of 3.67 mg/ml collagen (BD
Biosciences), and 15.7 ml 1N NaOH on ice to make 1 ml of gel
solution. The hydrogel was micropipetted onto a tissue culture
plate and placed within a humidified incubator at 5% CO2 and
37˚C to allow the hydrogel to gel.
Effects of Soluble QHREDGS on Endothelial Cell
Monolayers
Transwell assay. HMVEC-D were plated on collagen I-
coated 12 well Transwell plates (0.4 mm pore size polyester
membrane, 6.5 mm diameter inserts) in full EGM2 and grown to
confluence N = 3/group with experiments done in triplicate. Some
plates were stained using Giemsa to confirm confluence via
inverted phase contrast tissue culture microscopy. In wells
containing non-stained confluent cells, full media was removed
and changed to serum starvation media. Serum starvation media
was composed of EGM2 diluted 1 to 5 with endothelial basal
media 2 (EBM2) (Lonza). This resulted in a final serum
concentration of 1%. Cells were maintained in serum starvation
media for 1 hr (37uC, 5% CO2). Next, FITC-albumin (Sigma)
(1 mg/ml) was added to the top wells (1 hr, 37uC, 5% CO2).
Linear peptide QHREDGS, scrambled peptide DQSHGER, or
matched vehicle control (PBS) was added to a final concentration
of 400 mM of peptides (1 hr), human plasma-derived thrombin
was added at 2 U/ml (Calbiochem), and cells were incubated
(3 hr, 37uC, 5% CO2). Fluorescence was quantified using a
SpectraMax plate reader (excitation 485 nm/emission 538 nm).
The coefficient of albumin permeability (Pa) was calculated as
described [12] and Pa/Hr determined. The assay was performed
at least 4 times with N = 2/group for each repetition.
Transendothelial electrical resistance. Collagen I-coated
(10 min) ECIS electrode array eight chamber slides were rinsed
5X in Hank’s balanced salt solution (HBSS). HMVEC-D were
trypsinized and resuspended in phenol red free EBM (Lonza) plus
1X concentrations of EGM2 (Lonza). Then, ECs were plated and
cultured on collagen I-coated chamber slides (37uC, 5% CO2) in
full growth media in the ECIS 1600R chamber (Applied
Biophysics). When ECs were confluent, half of the full media
was removed and replaced with phenol red free EBM three times,
resulting in a serum starvation media containing 1/6 of the growth
factor concentration of full growth media. Linear peptide
QHREDGS Enhances Endothelial Cell Function
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QHREDGS, scrambled peptide DQSHGER, or matched vehicle
control (PBS) to a final concentration of 400 mM peptides was
added (1 hr, 37uC, 5% CO2). Next, thrombin was added at 2 U/
ml and cells incubated up to 3 days (37uC, 5% CO2).
Transendothelial electrical resistance was monitored throughout
the study (ECIS 1600) using N = 2/group with studies conducted
in triplicate. The assay was initiated without thrombin for 1 hr to
examine the permeability among conditions at baseline. The
permeability was assessed for up to 70 hr to demonstrate the
peptide’s effect at longer times.
Fluorometric nitric oxide assay. The MS1 ECs were
cultured in 96-well plates and rinsed twice in phenol red-free
DMEM (Invitrogen). Linear QHREDGS peptide, scrambled
QHREDGS peptide (DQSHGER), GRGDSP peptide (Syn-
BioSci), angiopoietin-2 (ang2), or ang1 (R&D Systems) or matched
vehicles (PBS) were added (N = 6/group with studies done in
duplicate) in phenol red-free DMEM/0.5% BSA and incubated
(0.5 hr, 37uC, 10% CO2). Then, 100 mM L-arginine (Sigma) was
added. Where indicated, 100 mM of S-Nitroso-N-acetylpenicilla-
mine (SNAP) (Calbiochem) was also added and cells were
incubated (1.5 hr, 37uC, 10% CO2). A quantitative fluorometric
extracellular NO assay (Calbiochem) was performed as per
manufacturer’s instructions. Since the final products of NO are
nitrates and nitrites, this assay uses nitrate reductase to convert
nitrates to nitrites, then uses 2,3-diaminonapthalene and NaOH to
convert nitrites to a fluorescent compound. Plates were read using
a Wallac 1420 Multilabel Victor3 microplate reader (Perkin
Elmer), with excitation at 355 nm and emission at 430 nm.
Survival and energetics assays. The MS1 ECs were
cultured in full media on 96 well plates. Cells were rinsed twice
in basal DMEM media (Invitrogen) and linear QHREDGS
peptide, scrambled QHREDGS peptide (DQSHGER), or vehicle
(PBS) were added in each cell’s basal media plus 0.5% BSA. Cells
were incubated for 1 day at 37uC, 10% CO2. MTT assays were
conducted as described [9]. ATP levels were quantified using the
CellTiter-Glo Luminescent Assay (Promega) as per manufacturer’s
instructions. NADH/NADPH levels were measured using the
CellTiter-96 Aqueous One Assay (Promega). Viability/NAD(P)H
levels were used following manufacturer’s instructions. For both
assays, N = 6/group, with studies done in duplicate. Luminescence
was measured using a Wallac 1420 microplate reader for ATP
studies and the optical density (OD) at 490 nm was measured to
assess NADH/NADPH levels.
Effects of QHREDGS Immobilized In Collagen-chitosan
Hydrogel on Endothelial Cells
Live/dead staining. Live/dead staining was performed on
N = 3 gels/group with a HUVEC seeding density of 187,500 cells
per hydrogel coated well of a 12 well plate and a working volume
of 1 ml during the 4 days of cultivation. The culture media was
changed fully every other day. Prior to application of the staining
solution, the gels were washed once with 16PBS (Gibco). The
live/dead staining solution (500 ml) consisted of 89% of the total
volume being culture media, 10.8% of the final volume being
1.5 mM propidium iodide (Invitrogen), and 0.2% of the final
volume being 10 mM 5-(and-6-)-Carboxyfluorescein Diacetate,
Succinimid – Mixed Isomers (CFDA-SE) (Invitrogen). After
30 min at 37uC, the staining solution was removed, the gels were
washed once with PBS, 200 ml of PBS was added back to the
solution and the samples were then observed under a fluorescence
microscope (IX81, Olympus). Live and dead cells were counted
using the cell counter plug in on ImageJ to determine cell viability.
CD31 staining and VE-CAD staining. Immunostaining was
performed on N = 3 gels/group with a HUVEC seeding density of
187,500 cells per hydrogel coated well of a 12 well plate and a
working volume of 1 ml during the 4 days of cultivation. The cells
were fixed in 4% paraformaldehyde for 20 min. The samples were
blocked in 10% normal goat serum (NGS) for 40 min at room
temperature followed by the application of the primary antibody
CD31 (Abcam, 1:200) or VE-CAD (Abcam, 1:100) for 18 hr at
4uC. For CD31 staining, the secondary antibody solution consisted
of 10% normal goat serum in PBS with 1:100 anti-mouse antibody
Alexa Fluor 488 (AbCam) and 1:100 DAPI added. For VE-CAD
staining the secondary antibody solution consisted of 1.5% normal
goat serum in PBS with 1:100 anti-rabbit antibody Rhodamine
(Jackson ImmunoResearch) and 1:100 DAPI added. The hydro-
gels were then covered for one hr and incubated at room
temperature. The hydrogels were then imaged under a fluores-
cence microscope (IX81, Olympus). CD31 images were used to
determine the average cell number and cell area per condition.
Cells were counted using the ImageJ cell counter feature for N = 3
gels/group. For area measurements, cells were traced using the
ImageJ free hand selection tool and the diameter was determined
using the ImageJ measure feature for N = 3 gels/group.
Caspase-3/7 assay. The amount of caspase-3/7 activity
after 3 days of culture on the three different hydrogel-peptide
concentrations was determined using the Apo-ONE caspase assay
(Promega) as per the manufacturer’s protocol. Briefly, 30,000
HUVECs were seeded onto the three different collagen-chitosan
hydrogel conditions in a 96 well plate. After 3 days of culture, the
cells had one of the three treatments applied in the culture media
for 17 hr: DMSO (1:1000), taxol dissolved in DMSO (2.5 mM)
and culture media control (no treatment). Following treatment the
caspase-3/7 assay was performed.
XTT assay. To normalize the caspase-3/7 activity to cell
number, an XTT assay was used to determine the number of cells
after three days of culture and 17 hr of treatment in the various
hydrogel-peptide groups and treatment conditions. The XTT
assay (Biotium) was performed according to the manufacturer’s
instructions and as we described previously [11]. A standard curve
of known cell numbers was created to correlate the colorimetric
data to cell number.
Encapsulation of Endothelial Cells in Collagen-chitosan
QHREDGS Hydrogels
Encapsulation time course studies: kinetics and tube-
formation. HUVEC encapsulation was performed with the
three hydrogel-peptide groups generated as described above. Once
the hydrogels had been created, before they were pipetted onto a
96 well plate, they were mixed with a specific number of cells so
that 35 ml of gel had 170,000 HUVECs (5?106 cells/ml of gel).
Once the hydrogel and cells had been mixed on ice, 35 ml of the
hydrogel/cell mixture was pipetted into a 96 well plate. The plate
was then placed into the incubator for 30 min (37uC and 5% CO2)
to allow the hydrogel to gel. After 30 min, 200 ml of culture media
was added to each sample and the plate was placed back into the
incubator with media changed every 2 days.
To image the HUVECs within the hydrogel, samples were
stained using CFDA-SE and imaged at days 2, 4 and 6 as
described in the above live/dead staining methods or with
CellTracker dye (Invitrogen) and imaged at 6, 18 and 24 hours
after seeding. Using CellTracker, encapsulated cells were stained
with a 2 mM solution of CellTracker dye in serum free media for
30 min (37˚C and 5% CO2). The staining solution was then
removed and the encapsulated cells were cultured in EGM2 for
30 min (37˚C and 5% CO2). The media was then removed and the
encapsulated cells were washed twice with PBS for 5 min. The
QHREDGS Enhances Endothelial Cell Function
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encapsulated cells stained with CellTracker dye were then fixed in
4% paraformaldehyde for 15 min and washed in PBS and imaged.
To determine the average longest construct path length, ImageJ
was used to draw the longest continuous path along a HUVEC
construct without back tracing on the current path. The longest
path was determined for all constructs within a single image and
then averaged. The average total path length was determined
through the addition of all the average longest construct path
lengths in an image.
At the end of cultivation of encapsulated cells, the samples were
fixed and stained for CD31 as described above. Confocal images
were taken using the Olympus FluoView 1000 Laser Scanning
Confocal Microscope with FV10-ASW 3.0 Viewer software.
Encapsulation integrin blocking assay. HUVEC encap-
sulation was performed with the three hydrogel-peptide groups
generated as described above. The hydrogel solution and the cells
were combined so that 35 ml of gel had 170,000 HUVECs (5?106
cells/ml of gel). Once the hydrogel and cells had been mixed on
ice, 35 ml of the hydrogel/cell mixture was pipetted into a 96 well
plate. The plate was then placed into the incubator for 30 min
(37uC and 5% CO2) to allow the hydrogel to gel. After 30 min,
control Igg antibody cardiac troponin-T (Thermo Scientific) at
6.75 mg/ml, anti-avb3 integrin (BD Biosciences) or anti-a5
integrin and anti-b1 integrin (BD Biosciences) were added at
50 mg/ml, concentrations proven effective in previous studies [13],
into the culture media and cultured for two days (37˚C and 5%
CO2).
1.7 Statistical Analysis
Statistical analysis was performed using SigmaPlot 12.0.
Differences between experimental groups were analyzed using
one-way and two-way ANOVA depending on the experiment. An
a= 0.05 was used for all tests and a normality test (Shapiro-Wilk)
and pairwise multiple comparison procedures (Holm-Sidak
method) were used for all ANOVA tests. If the equal variance
test failed, Kruskal-Wallis One Way Analysis of Variance on
Ranks was performed with all pairwise multiple comparisons
performed using the Tukey Test. P,0.05 was considered
significant for all statistical tests.
Results
QHREDGS Decreased Endothelial Cell Permeability upon
Thrombin Treatment
The effect that the peptide had on the permeability of
HMVEC-D was determined using a transwell assay. Figure 1A
shows that the peptide treated HMVEC-D significantly decreased
(P,0.004) the permeability of the confluent cell layer in
comparison to the control and the scrambled peptide group.
Next, the effect of the peptide on endothelial barrier function was
evaluated at baseline and in response to thrombin using a
transendothelial electrical resistance (TEER) assay, Figure 1B. At
time 0, all three groups had similar resistance. However, in the
group treated with the peptide QHREDGS, resistance rapidly
increased. At 1 hr, thrombin was added to induce endothelial cell
permeability and disrupt barrier function. Thrombin, which
disrupts endothelial cell barrier function, was added to each of
the three conditions of HMVEC-D culture and, resulted in a
decrease in resistance of the endothelial layer of all three
conditions. However, the resistance of the QHREDGS peptide
treated group recovered to a greater extent and remained at a
higher resistance level compared to the scrambled and control
treated HMVEC-D groups throughout the 70 hr study. Peptide
QHREDGS increased HMVEC-D barrier function at baseline
and with thrombin. Thus, similar to ang1 [14,15], peptide
QHREDGS attenuated EC permeability and improved intercel-
lular barrier integrity.
QHREDGS Enhanced Endothelial Cell NO Production and
Metabolism
The addition of the peptide to MS1 endothelial cell cultures
increased the release of nitric oxide in a dose dependent manner
(Figure 2A). Examining the effect ang1 had on nitric oxide
release, a statistically significant increase in comparison to the PBS
control was found at an ang1 concentration of 200 nM. The
control, RGD-based peptide sequence GRGDSP as well as ang2
did not show a statistically significant increase in nitric oxide
Figure 1. Linear QHREDGS Peptide Decreases Endothelial Cell
Permeability. (A) HMVEC-D were cultured on collagen I and
permeability was assessed using a Transwell assay (N= 3/group).
Endothelial cells were serum starved (1 hr) and FITC labeled albumin
was added to the top well and cells were incubated. QHREDGS or
scrambled (DQSHER) peptides at 400 mM or control (PBS) were added
(1 hr). Thrombin was added to induce permeability and the amount of
FITC-linked albumin in the bottom well was quantified (Pa/hr) (3 hr).
Peptide QHREDGS reduced HMVEC-D permeability (*P = 0.004) com-
pared to control and scrambled peptide (**P = 0.001) groups. (B)
Transendothelial electrical resistance was measured in HMVEC-D
cultured on collagen I. HMVEC-D were serum starved and QHREDGS
or scrambled (DQSHER) peptides at 400 mM or control (PBS) were
added (1 hr). Thrombin was added to reduce resistance and resistance
was measured as a function of time (N= 2/group). Peptide QHREDGS
increased QHREDGS resistance compared to control and scrambled
peptides. Red coloured triangles indicate normalized resistance values
for the QHREDGS treated group.
doi:10.1371/journal.pone.0072956.g001
QHREDGS Enhances Endothelial Cell Function
PLOS ONE | www.plosone.org 4 August 2013 | Volume 8 | Issue 8 | e72956
release in comparison to the PBS controls. Next, the peptide
QHREDGS, which is derived from ang1, was tested at two
different concentrations, 100 mM and 500 mM. Both concentra-
tions showed a statistically significant increase in nitric oxide
production in comparison to their respective PBS controls and
there was a dose response found with the 500 mM QHREDGS
peptide inducing a greater amount of nitric oxide produced
compared to the 100 mM condition. Figure 2B shows that when
MS1 endothelial cells were pre-treated with NO donor S-Nitroso-
N-acetylpenicillamine, the cells treated with either 200 nM of
ang1 or 500 mM of QHREDGS peptide released a significantly
greater amount of nitric oxide compared to their respective PBS
controls. No statistically significant difference was found between
the scrambled peptide group or the 100 mM QHREDGS and
their respective PBS controls.
The effect that the peptide had on MS1 endothelial cell survival
and metabolic activity in serum-starved conditions is shown in
Figure 3 through the measurements of MTT, ATP and
NAD(P)H levels. Figure 3A shows that in serum-starved
conditions, the peptide group had a significantly higher
(P = 0.001) amount of MTT being reduced, meaning more cells
were viable and active, in comparison to PBS controls. The
scrambled peptide group, DQSHGER, had similar MTT levels as
the PBS control. Additionally, in serum-starved conditions, the
QHREDGS peptide group had a significantly higher (P#0.03)
ATP level in comparison to the PBS control (Figure 3B). The
scrambled peptide group had a similar ATP level to the PBS
control. The QHREDGS peptide also significantly increased the
NAD(P)H levels in MS1 ECs in serum starved conditions
compared to the PBS control and scrambled peptide (P = 0.001;
Figure 3C).
Cultivation of HUVECs on QHREDGS Modified Collagen-
Chitosan Hydrogels Led to Improved Cell Viability
HUVECs cultured on the QHREDGS modified collagen-
chitosan hydrogels for 4 days had 84% viability for the control
hydrogel and 97% and 95% for the 100 mM and 650 mM peptide
modified hydrogel conditions (Figure 4A, C). Using One-Way
ANOVA, a statistically significant difference between the control
hydrogel and the 100 mM and 650 mM peptide modified hydrogel
conditions were found (P = 0.036 and P = 0.046).
CD31 is an integral membrane protein that mediates cell-to-cell
adhesion. CD31 is expressed constitutively on the surface of adult
and embryonic endothelial cells and mediates endothelial cell-cell
interactions and angiogenesis. CD31 staining for HUVECs
cultivated as monolayers on top of the collagen-chitosan hydrogels,
shown in Figure 5A, was positive for all three of the hydrogel
groups. There was a closer association of HUVEC membranes in
the 650 mM peptide hydrogel group, while the 100 mM peptide
hydrogel and control hydrogel groups showed HUVECs intercel-
lular connections were not as tight. Furthermore, the cells
cultivated on the 100 mM and 650 mM hydrogel had more
pronounced staining for VE-CAD compared to those cultivated on
the control hydrogel (Figure 5B). Cell area for HUVECs on each
of the three hydrogel groups, shown in Figure 5C, were found to
be comparable at 1360, 1270 and 1260 mm2 for the control,
100 mM and 650 mM peptide hydrogel groups. The average cell
density (Figure 5D) in each of the three hydrogel groups was also
found to be similar with values of 60,000, 70,000 and 65,000 cells/
cm2 for the control, 100 mM and 650 mM peptide hydrogel
groups. These data are consistent with known actions of ang1.
Ang1 does not promote EC proliferation [16] and as such,
QHREDGS was not expected to increase EC density or cell area.
However, similar to ang1 [17], peptide QHREDGS did increase
fortification of intercellular connections, as evidenced by the
change in CD31 and VE-CAD staining showing less space
between cells and more cell to cell connections.
QHREDGS Promotes Endothelial Cell Survival
Upon treatment with paclitaxel (taxol), capsase-3/7 activation
was significantly increased in cells cultivated on control and
peptide modified collagen-chitosan hydrogels with 650 mM
QHREDGS peptide in comparison to their respective PBS control
Figure 2. Linear QHREDGS Peptide Increases Nitric Oxide
Release from Endothelial Cells. (A) Mouse MS1 endothelial cells
were incubated with linear QHREDGS peptide, scrambled QHREDGS
peptide (DQSHGER), GRGDSP peptide, control (PBS), or 200 nM
angiopoietin-2 (ang2) or angiopoietin-1 (ang1) (0.5 hr). Then, 100 mM
L-arginine was added and cells incubated (1.5 hr). Extracellular nitric
oxide (NO) levels were measured (N= 6/group). In graphs, the mean
value is indicated with a bar. Linear QHREDGS peptide increased NO
levels at 500 and 100 mM (*P#0.00001) and ang1 also increased NO
levels (**P = 0.0002). Ang2, GRGDSP, and scrambled QHREDGS peptides
had no effect on NO levels compared to controls. (B) MS1 endothelial
cells were incubated with peptides and proteins as above, except SNAP
(NO donor) was added to the 1.5 hr incubation with L-arginine. In
graphs, the mean value is indicated with a bar. Linear QHREDGS
peptide at 500 mM and ang1 increased NO levels (*P,0.002). Scrambled
QHREDGS peptide and 100 mM QHREDGS did not affect NO levels.
Triangle color code: control (black), scrambled peptide (gray), QHREDGS
peptide (red), GRGDSP peptide (burgundy), ang2 (green) and ang1
(blue).
doi:10.1371/journal.pone.0072956.g002
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as well as their DMSO carrier alone (Figure 6). Interestingly,
when cells were cultivated on the peptide modified hydrogels with
100 mM QHREDGS, there was no statistically significant increase
in caspase-3/7 activation between the taxol, DMSO and PBS
conditions.
Lower Concentrations of QHREDGS Led to more Robust
Tube-Like Structure Formation by Encapsulated
Endothelial Cells
Upon encapsulation of HUVECs in QHREDGS modified
collagen-chitosan hydrogels, changes in tube-formation kinetics,
morphology, and organization were observed. We have performed
early stage vascular morphogenesis studies to better understand
the peptide’s effect on promoting EC tube-like structures
(Figure 7). The 18 and 24 hr time points for the peptide groups
exhibited more robust tube-like formations with the 100 mM
peptide group having the densest networks of tube-like structures
that were wider compared to those in the control or 650 mM
conditions (Figure 7). Over the course of 6 days, the HUVECs
found within the control hydrogel continued to show minor
changes in cell morphology and organization (Figure 8). The
majority of the cells remained rounded throughout the time
course. In the 100 mM peptide hydrogel group, the largest degree
of change in cell structure and morphology was observed. By day
2, many of the HUVECs had clustered together to form elongated
tube-like structures within the hydrogel with the peak of this
phenomenon occurring on day 4. By day 6, these tube-like
structures began to regress in both number and size. The 650 mM
peptide hydrogel displayed a faster and less pronounced effect than
the 100 mM peptide hydrogel group, with peak construct size and
elongation found on day 2 and regression beginning to occur on
day 4. Some HUVEC tubular structures remained at day 6 but
were smaller in comparison to those observed on day 2.
Quantification of the tube-like constructs was then performed
on day 4 hydrogels. Figure 8B shows the average longest single
path that can be drawn, without overlapping paths, on a HUVEC
tube-like structure. This result showed that the peptide hydrogel
groups had on average longer tube constructs in comparison to the
control hydrogel group with, the 100 mM peptide hydrogel group
having the largest average constructs of the three hydrogel groups.
A statistically significant difference in the longest path length was
found between the 100 mM peptide modified hydrogel and the
control hydrogel (P,0.05). Quantification of the size and
frequency of HUVEC constructs formed was performed by the
addition of all the total path lengths for a single image which was
then averaged across multiple images to give an average total path
length per image. The results, Figure 8C, showed that the
peptide modified hydrogels had a higher average total path length,
or in other words a higher abundance of HUVEC constructs, in
comparison to the control hydrogel group with the 100 mM
peptide hydrogel group having the highest average total path
length of the three groups. A statistically significant difference in
the total path length was found between the 100 mM peptide
hydrogel and the control hydrogel (P,0.05) as well as the 650 mM
peptide hydrogel and control hydrogel (P,0.05).
Confocal images of CD31 stained cells helped to better
elucidate the structure of the HUVEC tube constructs seen in
the encapsulation experiments (Figure 9). As was previously
stated, the peptide hydrogels had larger constructs in comparison
to the control hydrogel group. The control hydrogel constructs
were comprised of few cells with minimal cell elongation and
organization in both the day 4 and 6 images. In contrast, the
100 mM peptide hydrogel group had extensive tubes on day 4,
consisting of many elongated and connected cells staining strongly
for CD31. On day 6, the tube constructs began to regress even in
the 100 mM group. The 650 mM peptide group mirrored the
100 mM peptide hydrogel group, however, in general the construct
size and cell elongation at days 4 and 6 were smaller in the
650 mM peptide group compared to the control.
Integrins avb3 and a5b1 Mediate Tube Formation by
HUVECs in Peptide Modified Hydrogels
When the integrin receptor avb3 was blocked, the ability of
HUVECs to form robust tube-like structures in the peptide
modified hydrogels was hindered (Figure 10). When integrin
receptor a5b1 was blocked in the cells encapsulated in the peptide
modified hydrogels, HUVECs did not form tube-like structures,
Figure 3. Linear QHREDGS Peptide Increases Endothelial Cell
Survival and Energetics. (A-B) MS1 endothelial cells were incubated
with 500 mM QHREDGS or scrambled QHREDGS peptide (DQSHER) or
control (PBS) overnight. (A) Cells were incubated for 4 hr with MTT,
absorbances measured at 570 nm, and values normalized to cell
number (N = 5/group). Peptide QHREDGS increased MS1 endothelial cell
viability (*P = 0.001) as indicated by the increased processing of MTT by
mitochondria. (B) QHREDGS peptide increased endothelial cell ATP
levels, whereas scrambled QHREDGS had no such effect (*P = 0.03). (C)
MS1 endothelial cells were incubated with 500 mM QHREDGS or
scrambled QHREDGS peptide or control (PBS) for 3 hr. QHREDGS
peptide increased endothelial cell NADH/NADPH levels (*P = 0.05)
suggesting increased cellular energetics. Optical density (OD).
doi:10.1371/journal.pone.0072956.g003
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elongate or cluster and instead remained as round isolated cells.
The cells in the control hydrogel with blocked avb3 integrin,
exhibited a similar appearance as those cultivated with the control
Igg antibody, while a5b1 integrin blocking completely abolished
tube formation in the control hydrogel. Since integrin receptor
avb3 is specific to fibrin we did not expect a significant effect of its
blocking on the HUVECs ability to interact with the control
hydrogel which, is comprised of only collagen and chitosan. a5b1
is the shared integrin receptor for both collagen and fibrin, thus
the use of a5b1 integrin antibody prevented HUVEC’s interaction
with the major components of the hydrogel (collagen and
QHREDGS peptide), while blocking of avb3 integrin most likely
prevented HUVECs from interacting with the peptide only.
Discussion
Modified biomaterials are required to provide protection for
cells introduced into the hostile environment of a wounded tissue.
Consequently, many groups are focusing on discovering novel
peptides, derived from growth factors, to enhance the properties of
biomaterials and protect cell activity during the initial stage of
implantation. Presented in this paper is the use of a novel peptide,
QHREDGS, based on the fibrinogen-like domain of angiopoietin-
1, to enhance endothelial cell survival and preserve endothelial cell
functionality. We examined the effects of the soluble peptide on
endothelial cells cultured on tissue culture plastic as well as the
peptide covalently immobilized in a hydrogel suitable for
myocardial cell injection [11]. We demonstrated previously that
QHREDGS promoted survival and functional properties of
cardiomyocytes cultured in an in vitro collagen-chitosan hydrogel
[11]. The current study revealed that the peptide QHREDGS had
a dual protective effect for both cardiomyocytes and endothelial
cells. QHREDGS is thought to signal both cardiomyocytes and
endothelial cells through integrin binding domains since the
peptide is based on the fibrinogen-like domain of ang1. The cells
are thought to bind to QHREDGS via the aVb3 and/or a5b1
integrins [9,18], due to the homologous nature of the fibrinogen-
like domains of angptl3, ang1 and ang2 [9,19]. The dual
protective nature of QHREDGS positions the peptide as a
beneficial modifier of biomaterials for myocardial cell therapy.
Peptide sequences are being used in favour of growth factors, for
the modification of biomaterials, due to the plethora of issues
surrounding the use of growth factors. These include: a)
undesirable immune responses as the growth factors are often
isolated from non-human organisms, b) the proteins are subject to
proteolytic degradation, with further degradation occurring during
an inflammatory response, and c) their binding to biomaterials
could block the domain of interest making the growth factor
ineffective [20]. Specifically for ang1, the production of this
recombinant protein has been hindered by its insolubility and the
variability of the protein’s activity [21]. One peptide sequence of
much interest has been the cell binding motif Arg-Gly-Asp (RGD)
[22]. RGD has been used in many biomaterials to improve
endothelial cell adhesion, proliferation and migration
[20,23,24,25]. While the peptide that we present is thought to
also interact with endothelial cells through integrin binding
Figure 4. Cultivation of HUVECs on QHREDGS Modified Collagen-Chitosan Hydrogel Leads to Improved Viability. Characterization of
HUVECs on collagen-chitosan hydrogels with different peptide concentrations after 4 days of cultivation. 187,500 cells were seeded on the freshly
made hydrogels. (A) Control hydrogel, (B) 100 mM peptide hydrogel and (C) 650 mM peptide hydrogel with HUVECs stained for live/dead imaging
with CFDA-SE for live cells (green) and PI for dead cells (red). (D) Percentage of live cells. All images are 20X magnification with scale bar of 50 mm.
*P,0.05.
doi:10.1371/journal.pone.0072956.g004
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domains, QHREDGS also has the added functionality in its ability
to mitigate cell apoptosis.
Biomaterials implanted into patients need to ensure survival of
the encapsulated cells and promote the formation of a stable
vasculature with the host in order for cells suspended within the
biomaterial to survive implantation in the long term. We have
shown previously that the peptide QHREDGS can be effectively
conjugated to chitosan to create a peptide modified collagen-
Figure 5. QHREDGS Modified Collagen-Chitosan Hydrogels Support Expression of CD31 and VE-CAD in Endothelial Cells
Characterization of HUVECs on collagen-chitosan hydrogels with different peptide concentrations after 4 days of cultivation.
187,500 cells were seeded on the freshly made hydrogels. (A) HUVECs stained for CD31 (green) and cell nucleus (blue) in control, 100 mM peptide and
650 mM peptide hydrogels. 20X magnification with scale bar of 50 mm and higher magnification inset scale bar of 10 mm. (B) HUVECs stained for VE-
CAD (red) and cell nucleus (blue) stained in control, 100 mM peptide, and 650 mM peptide hydrogels. 40X magnification with scale bar of 20 mm. (D)
Average cell area. (E) Average cell number per cm2.
doi:10.1371/journal.pone.0072956.g005
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chitosan hydrogel [11]. The prior study by Rask et al. used a
photocrosslinkable Az-chitosan with the peptide QHREDGS
bound to chitosan. The material was spun coated and UV-
crosslinked onto glass cover slips [10]. The reason behind moving
away from the photocrosslinkable Az-chitosan to a collagen-
chitosan hydrogel was that we wanted to create a material that
could be easily injected into the heart and gel in situ rather than
requiring UV crosslinking, to avoid limitations of UV penetration
depth. The new in situ gelable formulation was demonstrated to be
suitable for culture of encapsulated heart cells and injection into
infarcted hearts [11].
Two other available alternatives to recombinant ang1 are
COMP-Ang1, which is a modified ang1 recombinant protein
containing a minimal coiled-coil domain [21], and Vasculotide,
which is an ang-based peptide-mimetic compound [26]. COMP-
Ang1 has been shown to improve endothelial cell barrier function,
mitigate radiation induced endothelial cell apoptosis and induce
the postcapillary venule and venous ends of capillaries to enlarge
due to endothelial cell proliferation leading to enhanced blood
flow [21,27,28]. However, COMP-Ang1 is still a recombinant
protein that could lead to a foreign body immune response.
Vasculotide has been shown to induce cell migration, MMP2
release, and protection from serum withdrawal-induced apoptosis
in endothelial cells [26]. Furthermore, Van Slyke et al. found that
Figure 6. QHREDGS Provides a Protective Effect on Endothelial
Cells Undergoing Apoptosis on Collagen-Chitosan Hydrogels.
Caspase-3/7 activity, normalized to cell number, is shown for each of
the three hydrogel-peptide concentrations. After three days of HUVEC
cultivation, each hydrogel group was treated three different ways for
15 hr. The treatments were: PBS control, DMSO carrier and Taxol
2.5 mM. * P,0.05, # P= 0.051.
doi:10.1371/journal.pone.0072956.g006
Figure 7. QHREDGS Modified Collagen-Chitosan Hydrogels Expedite Kinetics of Endothelial Cell Tube Formation. Encapsulation of
HUVECs within the control, 100 mM peptide and 650 mM peptide hydrogel groups with HUVEC membranes stained with CellTracker dye (red). Images
taken at 6, 18, and 24 hr to show the progression of HUVEC constructs forming within the hydrogel. All images were taken at 20X magnification.
Scale bar is 50 mm.
doi:10.1371/journal.pone.0072956.g007
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Vasculotide induced neovascularization in vivo, but its effect on
cardiomyocytes has not been explored. QHREDGS peptide could
be a more appealing modifier for cardiac cell therapy biomaterials
due to its dual effect of improving both cardiomyocyte [11] and
endothelial cell functionality.
Ang1 has been shown to have a variety of influences on EC
migration, permeability, inflammation and vascular maturation
[29] activating a number of signalling cascades through Tie2
receptor. Splitting ECs into two broad categories: 1) quiescent ECs
that are in contact with one another or 2) motile non-contacting
ECs; differences in the Tie2 receptor location on the cell were
discovered and lead to a greater understanding of ang1 situation
specific signalling [30,31]. In confluent ECs, ang1 induces Tie2
translocation to cell-cell contacts which results in the formation of
homotypic Tie2-Tie2 trans-associated complexes [31,32]. These
complexes then preferentially activate the AKT pathway resulting
in increased survival signals [33], increased endothelial NO
synthases (eNOS) synthesis [29] and reduced permeability through
the sequestration of Src by mDia which reduces the internalization
of VE-CAD [34]. When motile and non-contacting ECs are
stimulated by ang1 the Tie2 receptor is instead located preferen-
tially at cell-substratum contacts which facilitates ECM bound
ang1 to trigger Dok-R, ERK1/2 and MAPK signalling [30,31].
When ECs are stimulated by ang1 in this context, cell migration is
stimulated. Cascone et al. also demonstrated that there was an
association between Tie2 and the integrin a5b1 on ECs and that
this relationship was regulated through the engagement of a5b1 to
fibronectin [18]. The activation of a5b1 resulted in Tie2
phosphorylating at low ang1 concentrations yet, attenuated
activation at high ang1 concentrations. This combined a5b1-
Tie2 activation at a low concentration of ang1 resulted in
promoting EC survival and inducing persistent EC motility [18].
Preservation of endothelial cell barrier functional integrity,
protection against vascular leakiness investigated in microvascular
endothelial cells, and overall, improved endothelial cell health,
survival, and energetics are all characteristics associated with
peptide QHREDGS (Figure 1–3). Thus, QHREDGS has
overlapping functional effects on cardiomyocytes as shown in
our previous studies [10,11] and endothelial cells, as shown here.
NO is a short-lived molecular messenger formed from L-
arginine by NO synthases (NOS). NO made by endothelial NOS
in particular is vital to EC function and protects against
Figure 8. QHREDGS Modified Collagen-Chitosan Hydrogels Enhance Tube-Like Structure Formation of Encapsulated HUVECs.
Encapsulation of HUVECs within the control hydrogel and two peptide modified hydrogel groups. (A) HUVECs stained with CFDA-SE for live cells
(green). Images taken every other day to show the progression of HUVEC constructs forming within the hydrogel. (B) Average longest construct path
length determined on day 4. (C) Average total path length of constructs determined on day 4. * P,0.05. All images are taken at 4X magnification.
Scale bar is 200 mm.
doi:10.1371/journal.pone.0072956.g008
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hypertension and cardiovascular injury [35,36]. It is a potent
vasodilator and inhibits smooth muscle cell (SMC) proliferation
and migration, and matrix turnover [37]. NO is therefore
instrumental in both acute and chronic regulation of vascular
tone. Ang1 enhances NO production through Tie2 phosphoryla-
tion which leads to the phosphorylation of the p85 subunit of
phosphoinositide 3-kinase (PI3K), resulting in the activation of
AKT [33,38]. AKT has been shown to promote endothelial nitric
oxide synthase production [29].
By closely observing the y-axis scale in Figures 2A and B, it is
possible to see that the levels of NO were lower in all groups at
baseline condition (Figure 2A) compared to the levels in the
presence of SNAP, the NO donor (Figure 2B). QHREDGS
peptide and ang1, exhibited enhanced NO production upon
addition of L-arginine, compared to the control groups. In the
presence of a competing source for NO generation, namely SNAP,
the effects of QHREDGS peptide were dampened, as expected.
However, without SNAP-induced NO contributions, the effect of
QHREDGS peptide and ang1 alone were elaborated. The RGD
peptide had no effect on nitric oxide release at 500 mM
(Figure 2A). It also had no effect on cardiomyocyte survival at
any of the concentrations we tested in previous work [10,39], thus
we concluded it was not necessary to systematically use this control
in all of our experiments. It is possible that a greater effect of the
Figure 9. CD31 Staining of Tube-Like Structures is Enhanced in QHREDGS Peptide Modified Hydrogels. Confocal microscopy of
encapsulated HUVECs within the control hydrogel and two peptide modified hydrogels after 4 and 6 days of cultivation. CD31 (green) and cell
nucleus (blue). All images were taken at 20X magnification. Scale bar is 50 mm.
doi:10.1371/journal.pone.0072956.g009
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Figure 10. Blocking avb3 or a5b1 Integrin Receptor Inhibits Formation of QHREDGS Tube-Like Structures by Encapsulated HUVECs.
Encapsulation of HUVECs within the control hydrogel and two peptide modified hydrogel groups for two days in the presence of either an Igg
control, avb3 or a5b1 antibody. HUVECs stained with CFDA-SE for live cells (green). Images taken at the end of the two day cultivation to examine
tube-like structure formation. (A) Images taken at 4X magnification. Scale bar is 200 mm. (B) Images taken at 10X magnification. Scale bar is 100 mm.
doi:10.1371/journal.pone.0072956.g010
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QHREDGS peptide on NO release could be gained by using an
even higher concentration of the QHREDGS peptide, however,
these higher concentrations begin to move out of physiologically
relevant doses. We believe that the concentration ranges presented
provide the necessary information about the peptide’s ability to
instigate the release of nitric oxide and these also fall into the
ranges we investigated previously for their effects on cardiomyo-
cytes [11].
Ang1 has been shown to improve skin cell metabolism and
viability [40]. Consistent with this functional role, we showed that
ang1-derived peptide QHREDGS also promoted cell viability and
metabolism in ECs and in cardiomyocytes [9,10]. Furthermore,
ang1 did not promote EC proliferation, but it did increase EC
tube formation and survival, promoted tight junction formation
and reduced EC permeability [41]. Studies of both immobilized
and soluble peptide QHREDGS showed that this peptide reduced
EC permeability, increased electrical resistance, and fortified
endothelial cell-cell connections. Thus, the peptide QHREDGS
has the potential to prevent vascular leakage in pathologic settings
wherein increases in vascular permeability are problematic (e.g.
sepsis, tumor angiogenesis, proliferative diabetic retinopathy, age-
related macular degeneration, blood brain barrier breakdown).
The rationale for using 100 mM and 650 mM concentrations of
the peptide was based on previously reported data in our work
with cardiomyocytes [11]. These concentrations were found
beneficial for culture of cardiomyocytes compared to the
peptide-free control hydrogels. Since our ultimate goal is to create
a cell-delivery vehicle that would promote cardiomyocyte survival
and vascular tube formation, we investigated the same peptide-
hydrogel compositions with endothelial cells.
Here we showed that the peptide increased the viability of
HUVECs at both the 100 mM and 650 mM concentrations in
comparison to the control hydrogel. These studies were performed
using monolayers of endothelial cells on peptide modified
collagen-chitosan hydrogels (Figure 4–6) to ensure that we
observed the effect of the peptide irrespective of the effects related
to cell encapsulation such as diffusional limitations in oxygen and
nutrient supply [3]. As such, these studies enabled us to assess if the
peptide covalently immobilized into the hydrogel retained its
functionality in promoting cell survival. To ensure that this
statistically significant difference in viability (Figure 4) between
the peptide modified and non-peptide modified hydrogels was due
to the protective nature of the peptide and not due to the peptide
increasing proliferation or differential adhesion, cell number and
area were examined. It was found that the peptide likely did not
enhance endothelial cell proliferation as the average number of
cells per area was consistent between the three hydrogel groups
(Figure 5). As previously mentioned, cell area and cell density
assays were performed as monolayer studies of ECs on top of the
control and peptide modified collagen-chitosan hydrogels. Since
ECs were seeded at a high density and quickly established a
confluent monolayer, the effects of the peptide, we believe, would
be to promote quiescence in the cells and promote survival
similarly to what ang1 has been shown to do in this context specific
situation of a confluent monolayer of ECs [31,32].
HUVECs expressed CD31 in all three hydrogel conditions
(Figure 5). CD31 staining was performed to ensure that we had
an appropriate endothelial cell phenotype on our biomaterial at
the various QHREDGS concentrations. If CD31 staining was
absent, this would have indicated the hydrogel formulation was
not supportive for culture of endothelial cells and expression of
their phenotypic markers. CD31 has been shown to be involved in
a plethora of endothelial cell functions including: maintenance of
adherens junction integrity and permeability, organization of the
intermediate filament cytoskeleton, regulation of catenin localiza-
tion and transcriptional activities, participation in STAT isoform
signalling and control of apoptotic events [42,43].
However, in the 650 mM peptide group we saw that the
junction between HUVECs was stronger and less fenestrated in
comparison to the 100mM and control hydrogel. This dose
dependent relationship the peptide had on creating a less
permeable layer of endothelial cells was also seen during 2D
tissue culture plastic culture (Figure 1). It had been previously
shown that ang1 requires the IQ domain GTPase-activating
protein 1 as an activator of Rac 1 to regulate barrier function and
that this signalling cascade is initiated through the interaction of
ang1 and the Tie2 receptor [15,44].
Since the viability test combined with the cell number analysis
pointed towards the peptide’s role in cell survival as opposed to cell
proliferation, the protective effect that the peptide had on
endothelial cells stressed with paclitaxel was examined. We have
shown that there was no significant difference between the taxol
treated 100 mM peptide group and the basal levels of caspase-3/7
activation found in the PBS and DMSO controls at this peptide
concentration (Figure 6). Furthermore, we demonstrated a
statistically significant difference in the control and 650 mM
peptide groups, between the taxol treated cells and their respective
PBS controls (Figure 6). Since the most pronounced effect was
observed at 100 mM, there was no classical dose-dependency but
rather a maximum effect was observed at an intermediate
concentration. This kind of behaviour could parallel some of the
effects observed in previous studies with ang1. Cascone et al.
showed enhanced Tie2 activation and signalling at low ang1
concentrations through fibronectin sensitization [18]. They
demonstrated that ECs had a 4.4 fold increase in Tie2
phosphorylation with 20 ng/ml of ang1 as compared to only a
2.2 fold increase in Tie2 phosphorylation with 100 ng/ml of ang1
in the presence of a fibronectin based ECM [18]. They also
demonstrated that ang1 increased cell adhesion, independent of
ECM concentration (collagen, fibronectin or fibrinogen), with an
intermediate ang1 concentration being optimal [18]. These
findings correlate well with our findings of the 100 mM peptide
concentration exhibiting optimal effects in both the caspase-3/7
assay and the encapsulation experiments examining tube forma-
tion and cell kinetics.
Ang1 has been found in previous studies to help improve cell
survival by preventing apoptosis of endothelial cells when they are
under chemical stress or serum deprived conditions [6]. In
cardiomyocytes, the protective effect of ang1 was mediated by Akt
phosphorylation [9]. The anti-apoptotic effect of ang1 was also
found to be dose dependent in endothelial cells and was further
enhanced in the presence of VEGF [45]. In our study, we used
EGM2 media which contained 2% serum along with VEGF and
other endothelial growth factors. Our results, therefore, show a
combined protective effect that the peptide had at the lower
concentration along with VEGF and serum present in the media.
For confluent ECs, which is how our caspase assay was set-up,
ang1 was reported in previous studies to induce Tie2 translocation
to cell-cell contacts which resulted in the formation of homotypic
Tie2-Tie2 trans-associated complexes [31,32]. These complexes
were reported to then preferentially activate PI3K/Akt [46],
which resulted in the up-regulation of a broad spectrum apoptosis
inhibitor survivin [33].
To determine the behaviour of HUVECs cultured in a 3D
environment with the peptide, HUVECs were encapsulated within
the three hydrogel groups (Figure 7–10). We found that the
peptide modified hydrogels had an increased number of tube-like
structures and form these structures at a faster rate in comparison
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to the control hydrogel with the optimal concentration and time
point being 100 mM and 4 days. Ang1 has been shown to promote
HUVEC migration in the absence of any other ECM proteins,
macromolecules or serum [47]. Furthermore, EC migration has
been shown to be Tie2 independent but rather, based on one of
the b1 integrins [47]. While collagen was present within our
hydrogel and could be used to promote migration, the control
hydrogel showed a diminished ability to promote cells to organize
into tubes.
Tube formation typically involves EC proliferation and
sprouting in which tip cells acquire motile behaviour. The
extended cellular processes connect by lumen propagation through
intercellular and intracellular vacuole fusion [48]. Thus there are
many processes involved in tube formation and neovascularization
besides cell proliferation [49]. The role ang1 plays in signalling
various functionalities in endothelial cells is context dependent
based on whether or not ECs are isolated or surrounded by ECs,
as previously discussed [31,32].
In all three encapsulation conditions, regression of the tube-like
structures was observed at longer time points. Many primary cells
that are cultured in vitro cannot be sustained indefinitely. This is
due to the lack of a microenvironment that can provide all the
necessary mechanical and chemical cues. In this case, the lack of
many growth factors [50], absence of supporting cells such as
smooth-muscle cells and pericytes [51] and lack of proper matrix
stiffness or shear stress [52] for the ECs led to the eventual
regression of the tube-like structures.
To further evaluate which integrin this peptide may engage, we
performed a two day blocking experiment using integrin
antibodies. We chose to block either a5b1 or avb3 integrins of
encapsulated ECs in the three hydrogel conditions. By blocking
integrins a5b1 or avb3 for two days immediately after encapsu-
lation, we examined the role that these integrins may play in
enabling the cells to attach to the matrix and form tube like
structures. Since the QHREDGS peptide is from the fibrinogen-
like domain of ang1 [9], we were expecting to see ECs interact
with the peptide using the same integrins they use to interact with
fibrin. Furthermore, since the matrix we used was collagen, we
expected to see the most appreciable changes in tube formation
when both collagen and fibrin binding were blocked. We chose to
block the integrin receptor avb3 which is specific to EC interaction
with fibrin to tease out a specific role of the peptide, while not
hindering the EC’s ability to interact with collagen [13]. The other
integrin receptor blocked was a5b1 since the b1 unit may interact
with both collagen and fibrin [13,53]. Consequently, we expected
to see a graded response wherein blocking the integrin receptor
a5b1 would more strongly disrupt EC tube formation due to the
dual disruption of EC binding to the peptide and collagen matrix
while, blocking avb3 would only disrupt ECs ability to interact
with the peptide while still allowing for ECs to interact freely with
the collagen matrix. These integrin receptor blocking experiments
have 1) shown that the EC peptide interaction can be inhibited
through blocking integrin receptor avb3 and that 2) blocking
integrin receptor a5b1 resulted in isolated and round ECs after
two days of culture possibly due to blocking ECs from interacting
with both the peptide and collagen.
We believe that the differences in optimal concentrations for
monolayer studies (Figures 1–4) and the encapsulation studies
(Figures 7–10) are due to the way in which ECs were cultivated
and different ways in which the peptide was presented to the cells.
Specifically, Figures 1–3, deal with ECs that were cultured in a
monolayer and the peptide was applied in the soluble form. When
peptide was applied in soluble from, mass transport limitations
could be present which would effectively lower the peptide
concentration in the vicinity of the cell. When cells were cultivated
encapsulated in a hydrogel and the peptide was covalently
immobilized to the hydrogel material, the cells were surrounded
by the matrix and peptide which allowed for direct and sustained
interactions. Too high of a peptide concentration (e.g. 650 mM)
could induce cells to adhere too strongly, limiting their ability to
migrate and form tubes (as observed in Figure 8), thus
intermediate peptide concentrations may be most beneficial in
terms of the readouts we assessed in this paper. Similar effects were
reported previously for other peptides [54,55]. Our previous work
[11], focused on cardiomyocytes, found the optimal concentrations
to be 650 mM thus, the differences in the optimal peptide
concentrations may be cell type specific (cardiomyocytes vs.
endothelial cells).
This study showed that in a dose dependent manner, the
peptide QHREDGS can increase cell survival, decrease cell
permeability, and induce the formation of tube like structures. We
used several different endothelial cell lines (HMVEC-D, MS1 EC,
HUVEC) in order to confirm that the peptide acted on different
endothelial cell types, not just one type, in order to make sure the
peptide had a wide applicability. Furthermore, in conjunction with
previous studies of QHREDGS and its ability to improve
cardiomyocyte survival and function, this peptide has now been
shown to have a dual protective nature on endothelial cells and
cardiomyocytes. When conjugated to hydrogels, the peptide’s
function would be to help ensure initial survival of cells through
mitigation of cell apoptosis while stimulating the formation of a
primitive vasculature to rapidly form during the first few days to
provide oxygen and nutrients to the cells in the hydrogel. Further
studies are required to examine the functionality of a combined
endothelial cell and cardiomyocyte therapy for myocardial
infarction using a QHREDGS modified collagen-chitosan hydro-
gel in vivo.
Conclusion
We concluded from these experiments that the angiopoietin-1
based peptide QHREDGS was able to promote endothelial cell
connectivity, metabolism and survival of endothelial cells cultured
in monolayers with peptide applied in soluble form or when
covalently immobilized in collagen-chitosan hydrogels. When
endothelial cells were encapsulated within a peptide modified
collagen-chitosan hydrogel, the peptide was able to promote a
more rapid and robust response to form tube-like structures in
comparison to the control hydrogel. We propose that the peptide
QHREDGS would be an attractive candidate to modify solutions
and biomaterials for endothelial cell applications, in order to
promote cell survival and migration of cells leading to the
formation of new vasculature.
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